Drugs / HK-660S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06975150 | Aug 2025 → Aug 2028 expected | primary sclerosing cholangitis | CuromeBiosciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05866809 | Oct 2021 → Jun 2023 | primary sclerosing cholangitis | CuromeBiosciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HK-660S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06975150 ↗ |
| Route | Oral | “Administered orally” NCT05866809 ↗ |